Neoadjuvant Pazopanib in Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 7, 2015

Study Completion Date

February 15, 2017

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Pazopanib

800 mg orally once daily for 8 weeks, prior to nephrectomy

Trial Locations (2)

27599

North Carolina Cancer Hospital (UNC), Chapel Hill

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01361113 - Neoadjuvant Pazopanib in Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter